| Edward Roddy |
 |
| Edward Roddy is a Clinical Senior Lecturer in Rheumatology at Keele University’s Arthritis Research UK Primary Care Centre and Consultant Rheumatologist at the Haywood Hospital in Stoke-on-Trent, UK. He undertook training in general medicine and rheumatology in Nottingham and Western Australia. He has strong clinical and research interests in crystal athropathies, particularly gout, and leads epidemiological and qualitative studies, and clinical trials in primary care. He has co-authored best practice recommendations for gout by the British Society for Rheumatology (BSR), European League Against Rheumatism (EULAR) and the Arthritis and Musculoskeletal Alliance (ARMA) and has acted as a clinical advisor to NICE technology appraisals. "The pathogenesis of gout is the best understood of all types of arthritis. Hyperuricaemia is an essential prequisite for the development of gout, and shares many common risk factors with gout, including genetic factors, lifestyle factors, comorbidity, and specific medications. Key principles of the pathogenesis of gout will be summarised and related to clinical features. The evidence for common risk factors and comorbid disease associations will be examined" (Edward Roddy). |
|
| Professor Christian Mallen BMBS MMedSci PhD FRCGP |
 |
|
Christian Mallen is Professor of General Practice Research
and Director of Academic General Practice at the Arthritis Research UK Primary
Care Centre of Excellence, Keele University. His main research focuses on
improving the diagnosis and management of common musculoskeletal conditions in
primary care settings, with a particular interest in osteoarthritis, gout,
rheumatoid arthritis and polymyalgia rheumatica. He is currently a member of both the BSR and
EULAR gout clinical guideline groups and has contributed to the EULAR
taskforces on osteoarthritis and polymyalgia rheumatica. Speakers |
|
| |
|
| Dr Michelle Hui MBChB MRCP |
 |
| Michelle Hui is a full time practicing Consultant in Rheumatology at the Countess of Chester Hospital, Chester. She has clinical experiencing with managing a range of patients with gout and has developed local protocols used in primary and secondary care. She has delivered teaching sessions/talks on crystal arthritis and gout at a local and national level. She has experience with conducting systematic searches and has published in peer-reviewed journals. The talk on optimal urate-lowering therapy will cover:
|
|
| Professor Michael Doherty MA MD FRCP FHEA |
 |
| Michael Doherty is Professor of Rheumatology and Head of Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham. His main research interests are osteoarthritis (OA), gout, calcium pyrophosphate crystal deposition (CPPD), placebo/contextual response and evidence based medicine (EBM). He has expertise in clinical and epidemiological studies, community-based clinical trials, systematic reviews and meta-analyses. He has over 300 original research publications and was awarded the OA Research Society International (OARSI) Clinical Research Award for 2012. He is a past editor of Annals of the Rheumatic Diseases (1992-99), has co-chaired EULAR Task Forces for evidence-based recommendations for OA, gout and CPPD arthritis, and has been involved as a clinical expert in NICE appraisals relating to OA and gout. He was awarded a Lord Dearing prize for teaching and learning in 2001 and was the Royal College of Physicians Watson Smith Lecturer in 2011. "Gout is the only “curable” chronic joint disease but there are many barriers to care of people with gout, both in patients and health professionals. These include a focus only on acute attacks, stereotypic illness perceptions of overindulgence and alcohol excess, a comedic element, and lack of knowledge and undue concerns over urate-lowering therapy (ULT) in doctors. When properly informed almost all patients want ULT and adherence is excellent. Current suboptimal care of people with gout in the UK will be examined and key messages that need to be explained to all people with gout will be summarised" (Michael Doherty). |
|
| Professor Pascal Richette, MD PhD |
 |
Pascal Richette is Professor of Rheumatology in Lariboisière Hospital, Paris, France. His main research interests are osteoarthritis and gout, along with other crystal- related diseases, such as chondrocalcinosis and genetic hemochromatosis. PR is the president of the French Study group on OA.
The talk entiltled “Beyond Allopurinol and Febuxostat” will cover:
|
|
| George Nuki, MB FRCP FRCPE FFPM |
 |
| George Nuki is Emeritus Professor of Rheumatology in the University of Edinburgh. He has been involved in basic and clinical research related to gout for more than 40 years and is the author of some 250 research papers, book chapters and reviews. Recent work has included clinical trials, audit, health economic and epidemiological studies of gout and its treatment in Europe. The talk on management of acute attacks will discuss experience, research evidence and current BSR, EULAR and ACR guidelines for appropriate use of:
|
|
